Michael A. Schrader | Co-Founder and Chief Executive Officer
Vaxess Technologies, Inc

Michael A. Schrader, Co-Founder and Chief Executive Officer, Vaxess Technologies, Inc

Michael Schrader is the founding CEO of Vaxess Technologies, a Gates Foundation and venture-backed company developing next-generation vaccines on the MIMIX sustained-release microneedle platform. MIMIX combines high temperature stability, ease of administration, and enhanced immunogenicity through “infection mimicry” to create more effective vaccines that are easily delivered around the world. Prior to founding Vaxess, Michael spent time at Google, Toyota, and Honda R&D where he helped bring a wide range of products to market and earned fifteen patents for innovative new designs. Michael received his B.S. in Mechanical Engineering from Purdue University and his M.B.A. from Harvard Business School.


DC Co-conference Day 2 April 4 @ 3:10

Creating the next generation of vaccines and immunotherapies by mimicking an infection to enhance the immune response

  • Illustrating how the delivery of sustained release vaccine depots via microneedle patch improves immunogenicity
  • Logistical conquest in easy administration, shelf life stability and only minutes of wear time
  • Current progress with an in-house influenza vaccine and partnered programs to advance formulation for optimal patient uptake

back to speakers